Top 10 Healthcare ETFs

Risk Level: 🟡 Medium — Most funds here are steady core holdings, with a couple of higher-volatility biotech picks mixed in.

At a Glance

Data sources: ETF.com, Morningstar, and issuer fact sheets.
Ranking method: Sorted by AUM at the time of publication.
Risk lens: ETF entries are grouped into Core, Balanced, and High-risk buckets to help you match picks with your goals.

Gain diversified exposure to one of the world’s most essential, resilient, and innovative sectors. To see all of the sectors and strategies we cover, visit our Top 10 Rankings hub.

Simple guide: sector stability, fees, long-term growth.

Jump to: How to Use · FAQ

Why Healthcare ETFs Belong in Every Investor’s Portfolio

Healthcare is a defensive growth sector that continues to thrive regardless of market cycles. From major pharmaceuticals to medical devices and biotech breakthroughs, the healthcare industry delivers essential services and innovations that drive long-term returns. By investing in healthcare ETFs, you get diversified access to companies solving real-world problems, including drug development, disease prevention, and digital health solutions. Even when broader markets decline, healthcare often provides stability and steady performance. These funds can serve as a cornerstone for portfolios seeking a mix of growth, resilience, and long-term value. The ETF approach makes it easy to target both broad healthcare exposure and specialized sub-sectors like biotechnology, medical technology, and global pharma. To contrast health exposure with other themes, also explore Top 10 Value ETFs and Top 10 ESG ETFs. Many investors rotate into healthcare during periods of uncertainty because the sector feels familiar and reliable, making it easier to stay invested during market swings. This emotional comfort often leads people to overweight healthcare ETFs compared with other defensive sectors, especially when headlines make growth stocks feel risky.

The Top 10 Healthcare ETFs for 2026

Updated: December 01, 2025

Core (Top 5)

XLV
VHT
FHLC
IXJ
PPH

Balanced (3)

High-risk (2)

Color labels indicate investor fit. Core funds represent the largest and most diversified healthcare ETFs, offering broad exposure to pharmaceuticals, medical devices, and healthcare providers with steady, defensive long-term potential. Balanced funds include strategies with a mix of mid-cap, global, or more specialized healthcare holdings that provide meaningful growth opportunities with moderate day-to-day movement. High-risk funds focus on narrow or volatile segments such as biotechnology or medical innovation, where returns can swing sharply and fund longevity may vary. This list includes only non-leveraged healthcare ETFs with real scale, transparent methodologies, and consistent track records. All funds are ranked by assets under management (AUM) at the time of publication. Investors should always review each fund’s risks, consider their personal goals, and consult a qualified professional before making investment decisions.

1. Health Care Select Sector SPDR Fund (XLV)

XLV is the flagship healthcare ETF from State Street that gives investors broad exposure to the largest medical, pharmaceutical, and biotechnology companies in the United States. It is built to be simple, stable, and reliable, which is why many long-term investors treat it as their default healthcare building block. Because it focuses on established industry leaders, XLV tends to move more calmly than individual healthcare stocks.

The ETF is fully passive, tracks the S&P Health Care Select Sector Index, and follows a market-cap-weighted approach. This means the biggest companies set the tone for performance. For investors who want healthcare exposure without trying to pick winners manually, XLV offers a clean, low-cost way to own the entire sector.

XLV holds 63 companies and is heavily concentrated in health technology, pharmaceuticals, and medical services. The largest positions include Eli Lilly, Johnson & Johnson, AbbVie, and UnitedHealth. These companies dominate their segments and have long histories of innovation and consistent demand. Healthcare tends to stay resilient in all types of markets because medical needs do not disappear during recessions or slowdowns.

The ETF benefits from predictable cash flows, large-cap stability, and strong pricing power within the U.S. healthcare system. The expense ratio is just 0.08 percent, which is far below the average actively managed healthcare fund. Over long horizons, that cost advantage compounds into meaningful performance.

XLV earned its Core placement because it delivers the simplest, most reliable way to invest in the U.S. healthcare sector. Investors who want long-term stability often choose healthcare because people will always need treatment, medications, and medical procedures. XLV takes that idea and packages it into a diversified, low-fee fund that removes guesswork and reduces volatility. It fits naturally into Core allocations where steadiness, consistency, and long-term demand matter.

Growth Catalyst: The ongoing wave of obesity-drug demand, expanded pharmaceutical pipelines, and rising adoption of AI-driven diagnostics continues to drive strong revenue for XLV’s largest holdings.

Stat Nugget: XLV has delivered a 118.54 percent 10-year return according to the supplied snapshot, showing how durable the sector has been over long market cycles.

Explore more: See how healthcare compares to broad-market stability in Top 10 Blue-Chip Stocks.

Metric	Value
Price	$155.29
YTD Return	+12.88%
Expense Ratio	0.08%
Issuer	State Street (SPDR)
Index Tracked	S&P Health Care Select Sector Index
AUM	$40.84B
Dividend Yield	1.57%
Structure	ETF

XLV was chosen using a transparent, reader-first method that focuses on reliability, liquidity, and long-term usefulness for everyday investors. The ETF ranks extremely high in assets under management, long-term returns, and cost efficiency. It also benefits from a clear index methodology that is easy to understand. Because the fund invests in large, proven companies with durable demand, it fits cleanly into the Core bucket for this healthcare list. This selection approach avoids stock picking and instead focuses on real-world usefulness. Investors who want simple and steady exposure can rely on XLV as a foundational healthcare position.

XLV is best for investors who want calm, long-term healthcare exposure without having to track individual biotech or pharmaceutical news.

Price: $155.29

YTD Return: +12.88%

Expense Ratio: 0.08%

2. Vanguard Health Care ETF (VHT)

VHT is Vanguard’s broad healthcare ETF that invests across large, mid, and small companies in the medical and biotech industries. It offers much wider exposure than the sector’s biggest funds because it holds a massive 400 stocks instead of concentrating heavily on only the largest players. That makes it helpful for investors who worry about relying too much on just a handful of mega-cap pharmaceutical giants.

The ETF tracks the MSCI US Investable Market Health Care Index and includes everything from drugmakers to insurers to medical device innovators. Its 0.09 percent expense ratio keeps costs low, letting more of your returns stay in your pocket. VHT is built to provide long-term sector diversification without adding complexity.

VHT’s biggest advantage is its incredibly broad reach. While many healthcare ETFs lean heavily toward the largest pharmaceutical or health technology companies, VHT spreads its exposure across 400 holdings. This helps smooth out volatility when one part of the sector struggles, such as biotech pullbacks or insurance pricing pressures. Investors benefit from more even performance across the full spectrum of healthcare industries.

Its top holdings include Eli Lilly, AbbVie, UnitedHealth, and Johnson & Johnson, all companies with long-term demand and strong competitive positions. VHT’s blend of health technology, services, and distribution services allows investors to capture both steady cash flows and innovation-driven growth.

VHT earned its Core spot because it gives everyday investors an easy, one-stop healthcare solution that feels both safer and more complete than most sector funds. Many readers want exposure to healthcare but don’t know which corner of the industry will grow fastest or which biotech breakthroughs will hit. VHT solves that problem by giving you all of it, wrapped into a single, low-cost package. Its multi-cap structure makes it ideal for people who want diversification without extra decision-making.

Growth Catalyst: New pipelines in pharmaceuticals, increased insurance enrollment, and rapid improvements in medical device innovation help drive long-term growth across VHT’s biggest holdings.

Stat Nugget: VHT shows a 119.90 percent 10-year return in your snapshot, one of the strongest long-term performances among major healthcare ETFs.

Metric	Value
Price	$290.22
YTD Return	+14.40%
Expense Ratio	0.09%
Issuer	Vanguard
Index Tracked	MSCI US Investable Market Health Care 25/50
AUM	$17.74B
Dividend Yield	1.34%
Structure	ETF

VHT was selected because it checks every Core-investor box: broad diversification, low fees, strong liquidity, and long-term consistency. It avoids the problem of being too top-heavy, which makes it appealing for readers who want a smoother ride during market swings. The fund’s mix of large, mid, and small healthcare companies makes it a good match for investors who want growth potential without venturing into high-risk territory. This methodology focuses on solving the real research challenges investors face, such as not knowing which corner of healthcare will outperform next. Because VHT covers the entire sector in one fund, it provides a reliable long-term anchor for healthcare allocations.

VHT is a great fit for investors who want a simple, well-diversified healthcare position that balances stability with long-term growth potential.

Price: $290.22

YTD Return: +14.40%

Expense Ratio: 0.09%

3. iShares Biotechnology ETF (IBB)

IBB is iShares’ flagship biotechnology ETF, giving investors exposure to companies focused on drug development, genetic research, and advanced medical therapies. Biotech is known for big breakthroughs and big risks, so investors often struggle deciding which individual companies to pick. IBB solves that by bundling 253 biotech stocks into one fund, creating an easier and safer way to participate in medical innovation.

The ETF tracks the ICE Biotechnology Index and is market-cap weighted, meaning established leaders like Amgen, Gilead, and Vertex influence performance the most. This approach helps balance the sector’s natural volatility by focusing more heavily on proven players while still keeping exposure to younger research-driven firms.

IBB’s holdings are almost entirely in health technology subsectors, with a small amount in miscellaneous and commercial services. With top stocks like Vertex, Regeneron, and Alnylam leading the charge, the ETF captures both established biotech revenue streams and next-generation platforms such as gene editing and RNA-based treatments.

Biotechnology is one of the most research-intensive parts of the healthcare world. It can deliver huge gains when a breakthrough therapy succeeds, but it can also fall sharply when trials fail or approvals get delayed. IBB sits in the middle of that risk spectrum by providing wide diversification across hundreds of companies. This gives everyday investors a way to benefit from long-term scientific progress without the stress of watching individual clinical trial outcomes.

IBB earned its Balanced placement because it gives investors a mix of opportunity and stability in one of the most unpredictable parts of healthcare. Many readers want biotech exposure for long-term growth but aren’t comfortable picking single companies or handling extreme price swings. IBB helps solve that problem by spreading the risk across 253 holdings while still maintaining meaningful exposure to the industry’s biggest innovators. This makes it a practical middle-ground choice for someone who wants biotech upside without venturing into high-risk territory.

Growth Catalyst: Upcoming FDA decisions, expanding genetic therapy pipelines, and strong research funding create long-term tailwinds for IBB’s top holdings.

Stat Nugget: According to your snapshot, IBB has delivered a 53.10 percent 10-year return, showing the long-term value of broad biotech exposure even with its natural volatility.

Explore more: Learn how innovative sectors compare with broader growth themes in Top 10 Technology ETFs.

Metric	Value
Price	$170.11
YTD Return	+28.67%
Expense Ratio	0.44%
Issuer	Blackrock (iShares)
Index Tracked	ICE Biotechnology Index
AUM	$8.79B
Dividend Yield	0.16%
Structure	ETF

IBB was selected because it provides a well-balanced way to invest in biotech without requiring specialized research knowledge. Its combination of large proven companies and smaller research-focused firms helps spread risk while keeping long-term growth potential intact. This approach works well for readers who want exposure to biotech breakthroughs but also want to avoid the concentrated swings that come with pure high-risk biotech funds.

This method focuses on solving a common research problem for investors: understanding biotech without needing a scientific background. With IBB, the complexity is already handled for you through diversification and index design.

IBB is best for investors who want long-term biotech exposure but prefer a more stable, diversified approach instead of betting on individual companies.

Price: $170.11

YTD Return: +28.67%

Expense Ratio: 0.44%

4. SPDR S&P Biotech ETF (XBI)

XBI is a biotechnology ETF designed for investors who want aggressive exposure to the fastest-moving parts of the biotech world. Instead of concentrating in large, familiar companies, XBI uses an equal-weight design that gives smaller and mid-cap biotech firms much more influence on performance. This creates a high-risk, high-reward profile that can swing sharply based on news, clinical outcomes, and sentiment.

Many investors struggle to evaluate early-stage biotech companies because research timelines and FDA processes are complex. XBI solves that problem by spreading investments across 135 different biotech stocks. This gives investors a way to participate in breakthrough science without having to pick individual companies.

Biotech is one of the most unpredictable corners of healthcare, where stocks can jump or drop overnight based on trial data or regulatory announcements. XBI sits at the center of that volatility because equal-weighting amplifies exposure to smaller, more experimental firms. This makes the ETF behave very differently from funds like IBB, which lean toward large, established biotech names.

With nearly all holdings classified under health technology, XBI captures companies pushing boundaries in cancer therapies, genetic treatments, RNA medicines, and diagnostic innovation. But this innovation comes with greater price swings. In your snapshot, XBI’s volatility ranges from 1.69% to 2.37%, among the highest in the sector.

XBI earned its High-Risk placement because it gives investors powerful upside potential in exchange for meaningful volatility. Many readers want access to breakthrough biotech ideas but feel overwhelmed by stock-specific risk. XBI solves this by offering a diversified basket of smaller biotech names, letting investors participate in growth stories that could outperform dramatically if clinical trials succeed. At the same time, it requires comfort with sharper price swings than balanced or core funds.

Growth Catalyst: Continued breakthroughs in genetic engineering, cancer immunotherapy, and next-generation RNA platforms can drive explosive growth for many of XBI’s smaller names.

Stat Nugget: XBI shows a 72.25 percent 10-year return in your snapshot, highlighting how strong long-term results can still emerge despite heavy short-term volatility.

Metric	Value
Price	$119.85
YTD Return	+33.08%
Expense Ratio	0.35%
Issuer	State Street (SPDR)
Index Tracked	S&P Biotechnology Select Industry Index
AUM	$8.33B
Dividend Yield	0.04%
Structure	ETF

XBI was selected because it offers a clear path for investors seeking higher-risk healthcare exposure with the potential for outsized gains. Its equal-weight structure means new and emerging biotech firms get visibility instead of being overshadowed by industry giants. This design is ideal for readers who want more speculative exposure. It gives them access to companies working on cutting-edge therapies without having to analyze clinical data or track scientific milestones themselves.

This approach addresses a common investor problem: wanting biotech upside without relying solely on a few large companies. XBI spreads risk across many smaller names, letting investors capture the sector’s innovation cycle more evenly.

XBI is best for investors comfortable with big price swings who want access to fast-moving biotech innovation and understand that long-term success comes with high short-term volatility.

Price: $119.85

YTD Return: +33.08%

Expense Ratio: 0.35%

5. iShares Global Healthcare ETF (IXJ)

IXJ is a global healthcare ETF from iShares that lets investors own leading medical and pharmaceutical companies from around the world in a single fund. Many people struggle with deciding whether to invest only in U.S. healthcare giants or also include international players. IXJ solves that problem by blending both together, giving investors a much broader view of global medical innovation.

The ETF tracks the S&P Global 1200 Healthcare Sector Index and follows a market-cap-weighted approach. That means the world’s strongest healthcare companies, such as Eli Lilly, AstraZeneca, Roche, and Novartis, strongly influence performance. IXJ brings all of this together while keeping the structure simple, passive, and easy to understand.

Healthcare demand is global, and many of the most important medical breakthroughs come from outside the U.S. IXJ provides direct access to that wider ecosystem. From Swiss pharmaceutical powerhouses to Japanese medical device manufacturers and British biotechnology leaders, the ETF reflects the worldwide nature of healthcare development. This helps investors reduce the risk of relying solely on one country’s regulatory and economic environment.

IXJ remains heavily concentrated in health technology and pharmaceutical companies, which together represent more than 85 percent of the portfolio. This gives investors a strong foundation of proven companies while still capturing international diversity. For people who want a mix of stability and global reach, IXJ fills that need well.

IXJ earned its Core placement because it offers a simple, globally diversified healthcare portfolio inside one ETF. Many readers want healthcare exposure, but they are unsure if focusing only on U.S. companies limits their long-term opportunities. IXJ solves that concern by adding international leaders without complicating their overall investment approach. This makes it an ideal choice for investors who want both stability and global breadth.

Growth Catalyst: Expanding international demand for pharmaceuticals, increasing access to modern healthcare in developing regions, and strong pipelines from global drug manufacturers all support steady long-term growth.

Stat Nugget: IXJ’s 10-year return of 90.47 percent from your snapshot shows how global healthcare exposure can deliver strong, consistent results.

Explore more: Compare global diversification with domestic stability in Top 10 Dividend Stocks.

Metric	Value
Price	$97.38
YTD Return	+13.27%
Expense Ratio	0.40%
Issuer	BlackRock (iShares)
Index Tracked	S&P Global 1200 Healthcare Sector Index
AUM	$4.51B
Dividend Yield	1.42%
Structure	ETF

IXJ was selected because it provides a clean, diversified global healthcare option that removes the guesswork from choosing which countries or regions to focus on. It captures many of the world’s best-known pharmaceutical and medical technology names while keeping the structure low maintenance and passive. This makes IXJ a straightforward Core holding that supports long-term healthcare investing.

This selection approach helps investors who want global exposure but do not want to build international positions one by one. IXJ simplifies the process and ensures broad, steady coverage across global healthcare markets.

IXJ is best for investors who want long-term healthcare exposure with added global diversification, without needing to analyze international markets individually.

Price: $97.38

YTD Return: +13.27%

Expense Ratio: 0.40%

6. iShares U.S. Medical Devices ETF (IHI)

IHI offers investors a straightforward way to invest in the fast-growing U.S. medical devices industry. This corner of healthcare includes the companies that make surgical robots, diagnostic tools, imaging systems, and implantable devices that hospitals and clinics rely on every day. For many investors, choosing individual medical device stocks is challenging because the technology evolves quickly and products can be highly specialized. IHI solves this problem by packaging the industry’s largest and most dependable device makers into a single, easy-to-understand ETF.

The fund tracks the Dow Jones U.S. Select Medical Equipment Index and focuses heavily on established leaders with strong product demand. Its structure allows investors to benefit from both ongoing medical innovation and the steady need for essential equipment.

Medical devices sit at the heart of modern healthcare. These companies do not depend on clinical trial outcomes the way biotech firms do. Instead, they benefit from consistent demand as hospitals upgrade equipment, adopt minimally invasive procedures, and improve diagnostic accuracy. IHI captures this trend by holding companies such as Abbott, Stryker, Boston Scientific, and Intuitive Surgical, all of which have long-term demand for their products.

Because nearly all holdings fall under health technology, the fund maintains a focused profile while still offering diversified exposure across different areas of medical equipment. This gives investors a stable industry base with room for growth.

IHI earned its Balanced placement because it offers a smoother ride than biotech-heavy funds while still benefiting from powerful medical innovation. Many readers want exposure to cutting-edge healthcare technology but don’t want to deal with the sharp swings linked to experimental drug development. IHI solves this by investing in companies that already sell critical medical equipment worldwide, which adds predictability to long-term performance.

Growth Catalyst: Strong demand for robotic-assisted surgery, minimally invasive tools, and advanced diagnostic systems is driving rapid adoption across hospitals and research centers.

Stat Nugget: Over long periods, the medical device industry has delivered exceptional returns, supported by steady equipment demand and continuous product improvements.

Metric	Value
Price	$63.62
YTD Return	+9.03%
Expense Ratio	0.38%
Issuer	BlackRock (iShares)
Index Tracked	Dow Jones U.S. Select Medical Equipment Index
AUM	$4.35B
Dividend Yield	0.40%
Structure	ETF

IHI was selected for investors who want healthcare growth without taking on too much volatility. Medical device companies often benefit from recurring sales, established product lines, and incremental upgrades, making their performance easier to understand than research-dependent biotech companies. This structure helps investors participate in innovation while reducing the guesswork that normally comes with choosing healthcare stocks.

By focusing on companies with proven products and strong competitive positions, IHI offers a balanced way to capture long-term growth in a critical part of the healthcare system.

IHI is a strong fit for investors who want long-term exposure to medical innovation but prefer a more stable approach than what the biotech sector typically offers.

Price: $63.62

YTD Return: +9.03%

Expense Ratio: 0.38%

7. Fidelity MSCI Health Care Index ETF (FHLC)

FHLC gives investors an easy way to own the entire U.S. healthcare sector in one low-cost fund. Instead of picking individual healthcare stocks, which can be overwhelming, FHLC bundles many of the strongest companies in the industry into a single ETF. This solves a major problem for everyday investors who want reliable healthcare exposure without needing to understand each company’s products or financials.

Built on the MSCI USA IMI Health Care 25/50 Index, FHLC spreads its holdings across established leaders in pharmaceuticals, medical equipment, and healthcare services. This broader approach makes the fund more balanced than narrower sector ETFs.

Healthcare remains one of the most durable sectors in the market due to constant demand for medicine, treatments, diagnostics, and patient care. FHLC strengthens its position by investing in the largest and most stable healthcare businesses in the U.S. These companies tend to generate consistent revenue, even when the economy slows or markets weaken, which helps investors stay steady through volatile periods.

The fund leans heavily on health technology and health services, two areas that support long-term growth as the population ages, medical needs rise, and innovation continues.

FHLC earned its Core placement because it blends stability, strong long-term performance, and diversification across many parts of healthcare. Investors often want a simple, reliable healthcare ETF but do not want to overpay in fees or take unnecessary risks. FHLC solves this by maintaining a rock-bottom expense ratio and a balanced mix of high-quality companies.

Growth Catalyst: Expanding demand for medical devices, diagnostics, and pharmaceutical innovation is driving steady growth across the entire U.S. healthcare system.

Stat Nugget: FHLC’s extremely low expense ratio of 0.08 percent makes it one of the most cost-efficient healthcare ETFs available, helping investors keep more of their long-term returns.

Explore more: See how this compares with broader allocations in our Top 10 Value ETFs.

Metric	Value
Price	$74.75
YTD Return	+14.38%
Expense Ratio	0.08%
Issuer	Fidelity
Index Tracked	MSCI USA IMI Health Care 25/50 Index
AUM	$2.88B
Dividend Yield	1.37%
Structure	ETF

FHLC was selected because it offers simple, broad healthcare exposure at a cost that is difficult for other ETFs to match. It includes large, established companies that anchor the sector, which helps reduce volatility. At the same time, its index design ensures investors participate in innovation across pharmaceuticals, medical devices, hospital services, and related industries. This makes FHLC a dependable choice for anyone who wants healthcare exposure without taking on the sector’s most extreme risks.

FHLC is a strong fit for investors who want a low-cost, broad healthcare ETF built around stability and long-term growth.

Price: $74.75

YTD Return: +14.38%

Expense Ratio: 0.08%

8. VanEck Pharmaceutical ETF (PPH)

PPH gives investors an easy way to own many of the world’s most important pharmaceutical companies in one ETF. Instead of choosing individual drugmakers and trying to guess which treatments will succeed, PPH bundles proven industry leaders into a single investment. This solves a major problem for investors who want exposure to medicines and drug development without needing to track clinical trials or regulatory decisions. The fund includes companies that produce essential treatments used every day around the world. This focus provides both stability and steady long-term demand for their products.

Pharmaceutical companies operate at the core of healthcare. They develop medications for chronic conditions, life-saving therapies, and new treatments that drive medical progress forward. Because patients need consistent access to medicine, pharmaceutical businesses tend to experience steady demand even in uncertain economic periods.

PPH captures this stability by concentrating on large, established drugmakers with strong global distribution networks. These companies often have diversified product lines, helping them stay resilient when individual drugs lose exclusivity or face competitive pressure.

PPH earned its Core placement because it offers reliable, large-cap pharmaceutical exposure with less volatility than biotech-focused funds. Many readers want long-term healthcare growth but prefer avoiding the boom-and-bust cycles linked to experimental drug research. PPH solves that problem by focusing on companies with approved products, strong pipelines, and predictable revenue.

Growth Catalyst: Aging populations, rising global demand for chronic-care medications, and a steady flow of new drug approvals are driving ongoing growth in the pharmaceutical industry.

Stat Nugget: PPH’s one-year return of 17.49 percent highlights the strong performance of large, established drugmakers in the current market environment.

Metric	Value
Price	$87.84
YTD Return	+1.81%
Expense Ratio	0.36%
Issuer	VanEck
Index Tracked	MVIS US Listed Pharmaceutical 25 Index
AUM	$612.06M
Dividend Yield	1.94%
Structure	ETF

PPH was selected because it offers dependable exposure to pharmaceutical innovation without requiring investors to track every new therapy or research breakthrough. Its market-cap-weighted design naturally emphasizes the most stable and well-funded companies, which helps smooth out short-term market fluctuations. This makes the fund appropriate for investors who want predictable healthcare exposure rooted in essential products. By blending stability, global reach, and steady demand for medicine, PPH provides a solid foundation within the healthcare category.

PPH is a strong choice for investors who want reliable, large-cap pharmaceutical exposure backed by steady global demand for essential medicines.

Price: $101.10

YTD Return: +17.18%

Expense Ratio: 0.36%

9. iShares U.S. Healthcare Providers ETF (IHF)

IHF gives investors exposure to the companies that handle patient care, insurance coverage, and healthcare coordination across the United States. These providers are the backbone of the healthcare system because they keep the entire network running, from paying medical claims to managing hospital operations. For many investors, understanding individual healthcare provider stocks can feel complicated, since these companies often deal with insurance rules, regulations, and reimbursement models. IHF solves this by combining the biggest names in the space into a single ETF that is easy to understand.

The fund tracks the performance of major insurance carriers, hospital operators, and medical service companies, giving investors a simplified way to participate in a critical segment of healthcare.

Healthcare providers occupy a unique and essential role. They bridge the gap between patients, insurers, doctors, and treatment centers, which means they often generate steady, recurring revenue. Because patients need medical care regardless of the economy, the providers category tends to be more stable than other parts of healthcare, such as biotech.

IHF captures this stability through its heavy allocation to large, established firms that have millions of members, long-term contracts, and high switching costs. These features help protect revenue even when the wider market becomes uncertain.

IHF earned its Balanced placement because it sits between predictable stability and moderate sensitivity to economic conditions. Investors often want exposure to healthcare, but they may not want the rapid ups and downs that come from drug development or small-cap innovation. IHF solves this problem by focusing on insurance carriers and service providers that produce consistent cash flow but can still experience swings based on medical costs and policy changes.

Growth Catalyst: Rising enrollment in managed care plans, expanding access to insurance, and a growing population needing long-term care are helping drive steady demand for healthcare provider services.

Stat Nugget: IHF’s 10-year return of 106.46 percent shows how durable healthcare providers have been over long periods, even through market uncertainty.

Explore more: For broader exposure, review our Top 10 Total Markets ETFs.

Metric	Value
Price	$48.68
YTD Return	+1.44%
Expense Ratio	0.38%
Issuer	BlackRock (iShares)
Index Tracked	Dow Jones U.S. Select Healthcare Providers Index
AUM	$771.44M
Dividend Yield	0.79%
Structure	ETF

IHF was selected because it offers a focused way to invest in the companies that drive day-to-day patient care and insurance management. These businesses play a vital role in healthcare delivery, and their steady membership bases often help reduce volatility. The fund provides direct access to companies that manage hospital systems, handle insurance coverage, and coordinate treatments, all in one simplified portfolio.

This makes IHF a useful choice for investors who want healthcare exposure that is neither too speculative nor too conservative.

IHF is a smart pick for investors who want steady, service-focused healthcare exposure backed by long-term demand and large national provider networks.

Price: $48.68

YTD Return: +1.44%

Expense Ratio: 0.38%

10. Invesco Dorsey Wright Healthcare Momentum ETF (PTH)

PTH gives investors exposure to healthcare companies selected through a momentum-based strategy. Instead of focusing on size or stability, this fund holds the healthcare stocks showing the strongest recent performance. This structure helps investors who want a tactical approach without manually tracking market trends or timing individual trades.

The ETF relies on the Dorsey Wright relative strength methodology, which highlights stocks gaining traction in the market. For investors who want a more active, acceleration-driven style inside healthcare, PTH provides a ready-made option.

Healthcare momentum stocks tend to behave differently from traditional large-cap drugmakers or medical-device leaders. They can climb quickly during periods of innovation, strong earnings, or improving market sentiment. At the same time, they can fall sharply when momentum shifts, which makes them less predictable. PTH captures this space by holding smaller and mid-sized companies that move faster than the broader sector.

By using equal weighting and a relative-strength selection process, the fund spreads opportunity across many faster-moving companies rather than concentrating heavily on established giants.

PTH earned its High-Risk placement because it invests in healthcare stocks that can move quickly in either direction. Many readers want exposure to fast-growing companies but may not have time to track technical indicators or trading signals. PTH solves this by automatically rotating into the strongest-performing stocks across the healthcare universe.

Growth Catalyst: Momentum-driven healthcare companies can surge quickly when new products, clinical results, or earnings surprises create sharp performance spikes.

Stat Nugget: PTH’s 1-year return of 21.77 percent shows how quickly momentum can lift fast-moving healthcare stocks during favorable market periods.

Metric	Value
Price	$53.24
YTD Return	+32.98%
Expense Ratio	0.60%
Issuer	Invesco
Index Tracked	Dorsey Wright Healthcare Technical Leaders Index
AUM	$129.69M
Dividend Yield	N/A
Structure	ETF

PTH was chosen for investors willing to handle higher volatility in exchange for the potential to capture short-term surges in performance. The fund’s relative-strength methodology regularly updates the portfolio, ensuring it holds stocks with strong price trends. This approach brings more risk, but it also creates opportunities for outsized gains when momentum aligns with positive healthcare developments.

PTH provides a straightforward way to add tactical acceleration to a healthcare portfolio without having to manage each trade individually.

PTH is a good fit for investors who want fast-moving healthcare exposure and are comfortable with higher volatility in pursuit of stronger momentum-driven returns.

Price: $53.24

YTD Return:+32.98%

Expense Ratio: 0.60%

Take the Healthcare ETF quiz

5 quick questions • 60 seconds

How to Use This List

Set your goal: Decide if you want defensive exposure with big pharma and insurers, or higher growth potential from biotech and medical devices.

Pick your style: Choose a broad healthcare index ETF for stability, or a niche ETF (like biotech or genomics) if you want more upside and can handle volatility.

Build in layers: Use a broad ETF as your core, then add niche satellites if you want to tilt toward specific healthcare trends.

Read the key numbers: Always compare expense ratio, dividend/SEC yield, AUM, tracking error, and bid-ask spread to judge cost, income, and efficiency.

Set a review rhythm: Revisit after policy changes, drug-pricing news, or sector rotations. Adjust if one theme (like biotech) overtakes your intended mix. If you prefer direct equity exposure, see Top 10 Healthcare Stocks or broader market tools like Top 10 Total Market ETFs.

How We Chose These ETFs

To build this list, we analyzed the full U.S. healthcare ETF landscape using data from multiple top-tier sources, including Morningstar, ETF.com, Finviz, CFRA, Bloomberg, and official issuer disclosures. Our goal was to identify ETFs that offer clear thematic relevance across healthcare subsectors such as pharmaceuticals, biotechnology, medical devices, and healthcare services. Our selection criteria echo the methodology behind Top 10 Innovation ETFs and align with filters used for Top 10 Dividend ETFs.

This overview explains the criteria specific to this list. For a detailed explanation of how Impartoo’s Top 10 lists are researched, curated, and reviewed across all categories, see our Methodology.

Frequently Asked Questions

What is the expense ratio?
What: the annual fee charged by the fund, shown as a percentage of assets.
How: it’s deducted daily from the ETF’s value and already reflected in returns.
Why: lower expense ratios help more of your money stay invested and compounding.

What is dividend or SEC yield?
What: the income generated by the ETF’s holdings, expressed as a percent of price.
How: pharma and insurers often contribute steady dividends, while biotech usually reinvests cash.
Why: yield matters if you want income alongside growth.

What is AUM (Assets Under Management)?
What: the total dollar value of assets in the ETF.
How: reported by the issuer and updated daily.
Why: higher AUM often means more liquidity, tighter spreads, and less risk of fund closure.

What is tracking error?
What: the difference between ETF performance and its benchmark index.
How: calculated as the volatility of the return gap.
Why: lower tracking error shows the ETF is doing its job replicating the index.

What is the bid-ask spread?
What: the gap between the highest bid and lowest ask on the market.
How: shown in your brokerage’s live quote.
Why: tight spreads mean cheaper trading costs.

How do healthcare ETFs perform in downturns?
What: they often act defensively since people still need medicine and care.
How: broad funds with large pharma and insurers may drop less than the market.
Why: they can serve as a stabilizer in a diversified portfolio.

What role does biotech play in healthcare ETFs?
What: biotech adds growth potential but also more risk.
How: it depends on drug pipelines and FDA approvals.
Why: it can boost returns but also make funds more volatile.

How do policy changes affect healthcare ETFs?
What: laws on drug pricing, Medicare, or insurance rules can shift sector profits.
How: pharma and insurers are most sensitive; devices and tools less so.
Why: policy is a key driver of healthcare sector performance.

Are healthcare ETFs good for long-term investing?
What: yes, because aging populations and rising healthcare demand are long-term trends.
How: broad ETFs capture stable growth across sub-sectors.
Why: they can anchor a core portfolio position for years.

What’s the difference between broad and niche healthcare ETFs?
What: broad ETFs spread across pharma, devices, and insurers; niche funds may focus only on biotech or genomics.
How: niche ETFs concentrate holdings, which means bigger swings.
Why: broad funds suit steady investors, while niche funds appeal to risk-takers.

Final Thoughts on Healthcare ETF Investing

Whether you’re building a defensive core or looking to tap into innovation, healthcare ETFs offer a compelling mix of stability and upside potential. These funds cover everything from global blue-chip pharmaceutical giants to agile biotech disruptors, making them powerful tools for strategic asset allocation. As global populations age and medical technologies evolve, demand for healthcare will only grow. With a diversified healthcare ETF, you can position your portfolio to benefit from this long-term trend. Healthcare ETFs can serve as a defensive and growth hybrid, and pairing them with stability themes like
Top 10 Defensive Stocks or income plays such as Top 10 REIT ETFs may improve balance.

Explore More ETF Strategies

To expand your thematic toolkit, also browse Top 10 AI & Robotics ETFs, Top 10 Clean Energy ETFs, and Top 10 Cybersecurity ETFs. Looking to diversify even further? Check out our other Top 10 ETF lists, including Technology, ETFs, Dividend ETFs, and Total Market ETFs. Each one is vetted for clarity, conviction, and long-term portfolio value.